clinical trial · NCT04099732
A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Boehringer Ingelheim·phase1·completed·n = 26
HealthyRosuvastatinBI 1358894Dabigatran etexilate
brief summary
The main objective of this trial is to investigate the relative bioavailability of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1358894 (Test 1, Test 2) following oral administration.
started
Oct 7, 2019
primary completion
Dec 10, 2019
completion
Dec 10, 2019
last updated
Feb 27, 2025
official title
Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1358894 in Healthy Male Subjects (Open, Single-dose, Fixed Sequence, Two-period Crossover Design in Each Trial Part)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol